Bauer, Tobias http://orcid.org/0000-0002-0555-6214
von Wrede, Randi D.
Pujar, Suresh
Rácz, Attila
Hoppe, Christian
Baumgartner, Tobias
Varadkar, Sophia
Held, Nina R.
Reiter, Johannes T.
Enders, Selma
David, Bastian
Prillwitz, Conrad C.
Brugues, Mar
Keil, Vera C. W.
Jeub, Monika
Borger, Valeri
Sander, Josemir W.
Kunz, Wolfram S.
Radbruch, Alexander
Weber, Bernd
Helmstaedter, Christoph
Vatter, Hartmut
Baldeweg, Torsten
Becker, Albert J.
Cross, J. Helen
Surges, Rainer
Rüber, Theodor http://orcid.org/0000-0002-6180-7671
Funding for this research was provided by:
BONFOR research commission of the Medical Faculty of the University of Bonn (2022-1A-21)
Universitätsklinikum Bonn
Article History
Received: 3 April 2024
Revised: 19 July 2024
Accepted: 21 July 2024
First Online: 14 August 2024
Declarations
:
: R. D. von Wrede has received travel support, fees as speaker or for serving on the advisory board from Angelini, Apocare, Arvelle, Cerbomed, Desitin, Eisai, GW pharmaceuticals-JAZZ pharma and UCB Pharma; S. Pujar has received fees as speaker from UCB Pharma; V. Borger has received fees for serving as clinical consultant from Brainlab AG. J. W. Sander reports personal fees from Eisai, UCB Pharma and Angelini Pharma outside this work.A. Radbruch lectures for Guerbet and Bayer, and is part of the Advisory Board for GE, Bracco, and Guerbet; J. H. Cross has received support from Zogenix, Marinus, GW Pharma, Vitaflo, National Institute of Health Research (NIHR), EPSRC, GOSH Charity, ERUK, the Waterloo Foundation, and the Great Ormond Street Hospital NIHR Biomedical Research Centre and has served as a paid consultant/advisor for Zogenix/UCB, Biocodex and GW Pharma/Jazz, for which remuneration was made to the department, outside of the submitted work; R. Surges has received fees as a speaker or for serving on the advisory board from Angelini, Arvelle, Bial, Desitin, Eisai, Janssen-Cilag GmbH, LivaNova, Novartis, Precisis GmbH, UCB Pharma, UnEEG and Zogenix; T. Rüber has received fees as speaker from Eisai; the remaining authors have no conflicts of interest to declare.